H&H國際控股(01112.HK)首季總收入列賬基準計按年增長11.5%
H&H國際控股(01112.HK)公布,截至3月31日止三個月,總收入按呈報基準按年增長11.5%(按同類比較基準為7%)至26.83億元人民幣。
集團指,該增長主要歸因於內地、澳洲及新西蘭成人營養及護理用品業務的可觀穩健增長,以及寵物營養及護理用品業務持續的穩健增長趨勢,儘管嬰幼兒營養及護理用品分部面臨持續挑戰。該增長勢頭使集團有望於全年繼續保持整體升軌。
當中,內地的收入按同類比較基準按年增長2.6%,其中以Swisse為首的成人營養及護理用品實現33.3%增 長。澳紐市場的銷售持續好轉,按同類比較基準增長40.2%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.